Takeda shares data from phase 3 trial of CIPD treatment
Betsy Goodfellow | June 20, 2024 | News story | Research and Development | CIDP, Hyqvia, Neurology, Takeda, clinical trial
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase) in patients with chronic inflammatory dymyelinating polyneuropathy (CIDP).
The results of this trial demonstrated positive long-term safety and tolerability of the drug, with a low relapse rate, which supports its use as a maintenance treatment for this indication.
Full results are expected to be presented at a poster session at the Peripheral Nerve Society (PNS) Annual Meeting in Montreal, Canada, on Sunday 23 June 2024.
The trial demonstrated a median duration of Hyqvia treatment of 33 months with a cumulative overall follow-up time of 220 patient years. The findings were consistent with the known safety and tolerability profile of the drug and no new safety concerns were observed.
Kristina Allikmets, senior vice president and head of research and development for Takeda’s plasma-derived therapies business unit, commented: “The long-term data from the ADVANCE-CIDP 3 clinical trial allow us to further characterise the safety, efficacy and tolerability profile of Hyqvia and reinforces its role as a long-term, up-to once-monthly maintenance treatment for this complex, chronic condition. These results reflect our continued commitment to bringing the benefits of our differentiated immunoglobulin therapies to patients with neuroimmunological disorders, and providing a range of effective treatment options that address the individual needs of a broad range of patients.”
Betsy Goodfellow
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
